Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

Abstract

Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis.

Keywords

• Hepatocellular carcinoma (HCC)
• Hepatitis B virus (HBV)
• Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
• Reactivation
• Tenofovir alafenamide fumarate (TAF)